Lung cancer remains the leading cause of cancer-related mortality in both men and women
in the US and worldwide. Non-small cell lung cancer is the most common variety accounting …

Head and neck cancer is the sixth most common cancer across the globe. This is generally
associated with tobacco and alcohol consumption. Cancer in the pharynx majorly arises …

Rapidly develo** molecular biology techniques have been employed to identify cancer
driver genes in specimens from patients with non-small cell lung cancer (NSCLC). Inhibitors …

In the United States, lung cancer is the second most frequently diagnosed type of cancer
and the leading cause of cancer deaths. 1 Non–small-cell lung cancer (NSCLC), which …

Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the
leading causes of cancer-related death worldwide. Despite many therapeutic advances in …

Objectives There is an expanding list of therapeutically relevant biomarkers for non-small
cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition …

Background Dysregulated expression and activation of receptor tyrosine kinases (RTKs) are
associated with a range of human cancers. However, current RTK-targeting strategies exert …

Tyrosine Kinase Inhibitors - StatPearls - NCBI Bookshelf US flag An official website of the
United States government Here's how you know NIH NLM Logo Access keys NCBI Homepage …

Introduction Numerous therapeutic agents specifically targeting the mesenchymal-epithelial
transition (MET) oncogene are being developed. Objective The aim of the current review …

METex14 skip** mutations occur in about 3–4% of lung adenocarcinoma patients and 1–
2% of patients with other lung cancer histology. The MET receptor tyrosine kinase and its …